Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance

Table 1

Patient and donor characteristics, and antiviral therapy at the time the ISH biopsy in HCV ISH positive (group 1) and negative (group 2) patients.

Variables	Group 1 ISH positive 𝑁=10	Group 2 ISH negative 𝑁=15	𝑃
Patient age at LT	49 ± 11	52 ± 11	.66
Female gender (patient)	40%	13%	.13
Caucasian (patient)	90%	87%	.69
Recipient body mass index	31 ± 7	29 ± 6	.51
MELD at LT	14 ± 5	18 ± 9	.42
Genotype 1 (unknown in 1 patient per group)	56%	86%	.11
Donor age	47 ± 13	43 ± 14	.82
Female gender (donor)	40%	53%	.51
Caucasian (Donor)	90%	67%	.34
Cold ischemia time, hours	7 ± 2	7 ± 2	.74
Warm ischemia time, minutes	39 ± 9	34 ± 10	.28
Tacrolimus as primary immune suppressant	100%	83%	.23
Steroid bolus treated ACR	30%	40%	.61
LT to ISH biopsy interval, months	23 ± 10	24 ± 12	.91